SI2969099T2 - Odstranjevanje izluženega afinitetnega purifikacijskega liganda - Google Patents

Odstranjevanje izluženega afinitetnega purifikacijskega liganda

Info

Publication number
SI2969099T2
SI2969099T2 SI201430759T SI201430759T SI2969099T2 SI 2969099 T2 SI2969099 T2 SI 2969099T2 SI 201430759 T SI201430759 T SI 201430759T SI 201430759 T SI201430759 T SI 201430759T SI 2969099 T2 SI2969099 T2 SI 2969099T2
Authority
SI
Slovenia
Prior art keywords
leaked
removal
affinity purification
purification ligand
ligand
Prior art date
Application number
SI201430759T
Other languages
English (en)
Slovenian (sl)
Other versions
SI2969099T1 (sl
Inventor
Samuel Ray Trejo
Robert Perry Brake
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50424772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2969099(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of SI2969099T1 publication Critical patent/SI2969099T1/sl
Publication of SI2969099T2 publication Critical patent/SI2969099T2/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201430759T 2013-03-14 2014-03-11 Odstranjevanje izluženega afinitetnega purifikacijskega liganda SI2969099T2 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361785038P 2013-03-14 2013-03-14
PCT/US2014/023682 WO2014159441A1 (en) 2013-03-14 2014-03-11 Removal of leaked affinity purification ligand
EP14714890.2A EP2969099B2 (en) 2013-03-14 2014-03-11 Removal of leaked affinity purification ligand

Publications (2)

Publication Number Publication Date
SI2969099T1 SI2969099T1 (sl) 2018-09-28
SI2969099T2 true SI2969099T2 (sl) 2022-04-29

Family

ID=50424772

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201430759T SI2969099T2 (sl) 2013-03-14 2014-03-11 Odstranjevanje izluženega afinitetnega purifikacijskega liganda
SI201432052T SI3395423T1 (sl) 2013-03-14 2014-03-11 Odstranjevanje izluženega liganda za afinitetno čiščenje

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201432052T SI3395423T1 (sl) 2013-03-14 2014-03-11 Odstranjevanje izluženega liganda za afinitetno čiščenje

Country Status (17)

Country Link
US (3) US20160024144A1 (enExample)
EP (3) EP3395423B1 (enExample)
JP (1) JP6457479B2 (enExample)
AU (1) AU2014240596B2 (enExample)
CA (1) CA2904411A1 (enExample)
CY (1) CY1120353T1 (enExample)
DK (2) DK2969099T4 (enExample)
ES (2) ES2964601T3 (enExample)
FI (1) FI3395423T3 (enExample)
HU (2) HUE038565T2 (enExample)
LT (2) LT3395423T (enExample)
MX (2) MX365501B (enExample)
PL (2) PL3395423T3 (enExample)
PT (2) PT3395423T (enExample)
SI (2) SI2969099T2 (enExample)
TR (1) TR201809050T4 (enExample)
WO (1) WO2014159441A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2964601T3 (es) 2013-03-14 2024-04-08 Amgen Inc Eliminación de ligando de purificación por afinidad filtrado
AR096713A1 (es) * 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales
EP3155009A1 (en) * 2014-06-13 2017-04-19 Lupin Limited Process for the purification of tnfr:fc fusion protein
CN105214341B (zh) * 2015-09-17 2017-12-15 广州康盛生物科技有限公司 组合型吸附柱及其制备方法
US20200283472A1 (en) * 2016-03-29 2020-09-10 Navya Biologicals Pvt. Ltd A process for purification of fc-fusion proteins
US12516102B1 (en) 2017-02-09 2026-01-06 Bracco Suisse Sa Process for the purification of soluble PSGL-1 protein variants
CN118047854B (zh) * 2024-02-26 2024-08-02 武汉鹰达生物科技有限公司 一种人载脂蛋白a-i的分离纯化方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
DE3811042A1 (de) 1988-03-31 1989-10-19 Merck Patent Gmbh Ionenaustauscher
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
ATE236249T1 (de) 1989-09-12 2003-04-15 Hoffmann La Roche Tfn-bindende proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
ES2198414T3 (es) 1992-10-23 2004-02-01 Immunex Corporation Procedimientos para preparar proteinas oligomericas solubles.
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
DE4333821A1 (de) 1993-10-04 1995-04-06 Merck Patent Gmbh Ionenaustauscher
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
DE19501726A1 (de) 1995-01-20 1996-07-25 Merck Patent Gmbh Polymerisationsfähige Derivate von Polyamiden
AU708239B2 (en) 1995-06-29 1999-07-29 Immunex Corporation Cytokine that induces apoptosis
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
ATE204004T1 (de) 1996-06-21 2001-08-15 Merck Patent Gmbh Polymere sorbentien auf basis polymerisationsfähiger derivate von polyamiden
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6398962B1 (en) 1997-06-18 2002-06-04 Merck Kgaa Use of monolithic sorbents for preparative chromatographic separation
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
CA2469815C (en) 2001-12-21 2011-05-03 Immunex Corporation Methods for purifying protein
MX2007011129A (es) * 2005-03-11 2007-11-06 Wyeth Corp Un metodo de cromatografia de particion debil.
CN102887955A (zh) * 2006-04-05 2013-01-23 艾博特生物技术有限公司 抗体纯化
SI2078071T1 (sl) * 2006-11-08 2015-05-29 Wyeth Llc Racionalno zasnovana gojišča za celično kulturo
TW201024318A (en) * 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
US20120141497A1 (en) * 2009-03-11 2012-06-07 Wyeth Llc Methods of purifying small modular immunopharmaceutical proteins
ES2603396T3 (es) * 2010-07-30 2017-02-27 Pfizer Inc Purificación en tándem de proteínas
WO2012176158A1 (en) 2011-06-24 2012-12-27 Dr. Reddy's Laboratories Limited Purification of chimeric protein
AU2012282960A1 (en) * 2011-07-08 2014-01-16 Merck Sharp & Dohme Corp. Method for purifying Fc-fusion protein
EP2773671B1 (en) * 2011-11-04 2021-09-15 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
SG10201701224UA (en) * 2012-03-12 2017-04-27 Merck Patent Gmbh Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode
ES2964601T3 (es) 2013-03-14 2024-04-08 Amgen Inc Eliminación de ligando de purificación por afinidad filtrado

Also Published As

Publication number Publication date
SI3395423T1 (sl) 2023-12-29
WO2014159441A1 (en) 2014-10-02
PL2969099T3 (pl) 2018-10-31
ES2674697T5 (es) 2022-04-19
CY1120353T1 (el) 2019-07-10
EP3395423A1 (en) 2018-10-31
AU2014240596A1 (en) 2015-09-24
PT2969099T (pt) 2018-07-05
HUE038565T2 (hu) 2018-10-29
TR201809050T4 (tr) 2018-07-23
SI2969099T1 (sl) 2018-09-28
LT3395423T (lt) 2023-12-11
MX2019006568A (es) 2019-08-22
PT3395423T (pt) 2023-11-14
DK3395423T3 (da) 2023-11-20
JP2016513643A (ja) 2016-05-16
LT2969099T (lt) 2018-09-10
EP2969099B1 (en) 2018-04-25
MX2015011994A (es) 2015-12-01
MX365501B (es) 2019-06-05
HK1220159A1 (en) 2017-04-28
EP2969099A1 (en) 2016-01-20
JP6457479B2 (ja) 2019-01-23
EP3395423B1 (en) 2023-09-20
US11192919B2 (en) 2021-12-07
PL2969099T5 (pl) 2022-06-13
FI3395423T3 (fi) 2023-11-02
ES2964601T3 (es) 2024-04-08
PL3395423T3 (pl) 2024-03-18
HUE064450T2 (hu) 2024-03-28
ES2674697T3 (es) 2018-07-03
EP2969099B2 (en) 2021-12-22
AU2014240596B2 (en) 2018-09-27
US20160024144A1 (en) 2016-01-28
DK2969099T3 (en) 2018-07-09
DK2969099T4 (da) 2022-03-14
EP4026596A1 (en) 2022-07-13
MX391507B (es) 2025-03-21
CA2904411A1 (en) 2014-10-02
US20220144886A1 (en) 2022-05-12
US11492372B2 (en) 2022-11-08
US20190085021A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
IL240718A0 (en) filtering
IL244095A0 (en) Modulators of complement factor b
GB201314217D0 (en) Coolant purification
PL3263994T3 (pl) Filtry
PL3068854T5 (pl) Usuwanie niepożądanych składników propanolu
SG11201603028SA (en) Purification of proteins
GB201303016D0 (en) Filter
GB2517985B (en) Sheaf-based fluid filter
HUE064450T2 (hu) Kiszivárgott affinitás tisztító ligandum eltávolítása
GB201303024D0 (en) Filter
ZA201603797B (en) Novel purification processes
GB201303013D0 (en) Filter
GB201310928D0 (en) New Processes
GB201303018D0 (en) Filter
GB201303027D0 (en) Filter
GB201303033D0 (en) Filter
GB201303636D0 (en) Chamber fluid removal system
GB201303019D0 (en) Filter
GB2515553B (en) Coolant purification
PL3063156T3 (pl) Sposób oczyszczania lecytyny
GB201314581D0 (en) Purification
GB201303030D0 (en) Filter
GB2512032B (en) Filter
GB201315128D0 (en) Gas Filter
GB201318565D0 (en) New processes